SCHEMBL7916765

SCHEMBL7916765

O=C(O)c1ccc2cccc(-c3cccnc3F)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2D Q9UNK4 1/20 0.48
DHODH Q02127 4/20 0.45
NAPRT Q6XQN6 1/20 0.44
PLAU P00749 1/20 0.44
SLC40A1 Q9NP59 1/20 0.41
PTPN1 P18031 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RORC P51449 1/20 0.39
POLB P06746 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2C Q14957 1/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16502608 0.84 SLC40A1 (0.50) PLA2G2DPLAUSLC40A1PTPN1SMN1; SMN2
SCHEMBL16502512 0.84 ALOX15 (0.54) SLC40A1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL16502630 0.84 PLA2G2D (0.46) PLA2G2DDHODHPLAUSLC40A1PTPN1
SCHEMBL16502597 0.83 CYP3A4 (0.45) PLA2G2DPLAUSLC40A1PTPN1MEN1
SCHEMBL16502462 0.83 DHODH (0.45) PLA2G2DDHODHNAPRTPLAUSLC40A1
SCHEMBL16502774 0.82 HTR5A (0.50) PLAU
SCHEMBL16502535 0.82 PLA2G2D (0.44) PLA2G2DDHODHNAPRTPLAUPTPN1
SCHEMBL16502559 0.81 PLA2G2D (0.46) PLA2G2DDHODHPLAUPTPN1MEN1
SCHEMBL16509468 0.80 SLC22A12 (0.45) PLA2G2DPLAUSLC40A1PTPN1MEN1
SCHEMBL16502697 0.80 PLA2G2D (0.45) PLA2G2DDHODHNAPRTPLAUPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A PLA2G2D 841/4885DHODH 1737/4885NAPRT 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.